{
    "nctId": "NCT06570031",
    "briefTitle": "ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer",
    "officialTitle": "ONO-4578-06: Phase I , Open-label, Non-blind, First-line Endocrine Therapy With ONO-4578 and Standard Treatment Letrozole and CDK4/6 Inhibitors (Palbociclib or Abemaciclib) in Patients With Metastatic or Recurrent Postmenopausal Hormone Receptor-positive HER2-negative Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with postmenopausal metastatic or recurrent breast cancer\n2. Patients with ECOG Performance Status 0 to 1\n3. ER-positive, PgR-positive and HER2-negative patients\n\nExclusion Criteria:\n\n1. Patients are unable to swallow oral medications\n2. Patients with severe complication",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}